Butorphanol versus Propofol in Patients Undergoing Noninvasive Ventilation: A Prospective Observational Study
Authors Wang X, Meng J
Received 14 December 2020
Accepted for publication 23 February 2021
Published 22 March 2021 Volume 2021:14 Pages 983—992
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Scott Fraser
Xiaohong Wang,1 Jianbiao Meng2
1Intensive Care Unit, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, 310003, People’s Republic of China; 2Intensive Care Unit, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang Province, 310012, People’s Republic of China
Correspondence: Jianbiao Meng
Intensive Care Unit, Tongde Hospital of Zhejiang Province, #234 Gucui Road, Hangzhou, Zhejiang Province, 310012, People’s Republic of China
Email [email protected]
Background: The present study aimed to explore sedation management in agitated patients who suffered from acute respiratory failure (ARF) and were treated with noninvasive ventilation (NIV).
Patients and Methods: We divided 118 patients undergoing NIV treatment with butorphanol or propofol into two groups: group B (n = 57, butorphanol was initiated at the rate of 0.12 μg/kg/min as a continuous intravenous infusion and then titrated by 0.06 μg/kg/min every half an hour, group P (n = 61, propofol was initiated at the rate of 5 μg/kg/min as a continuous intravenous infusion and then titrated by 1.5 μg/kg/min every half an hour). Score of Sedation Agitation Scale (SAS) in the two groups was maintained between 3 and 4. Medications including sedative, analgesic, and antipsychotic, NIV intolerance score, SAS score, visual analog scale (VAS), medication use and adverse events were recorded repeatedly.
Results: Patients receiving butorphanol required significantly less total amount of fentanyl than patients receiving propofol during NIV to maintain the target VAS [0 (0– 0) μg vs 150 (50– 200) μg, P< 0.005]. Hemodynamic stability during NIV showed it was better kept in patients treated with butorphanol.
Conclusion: Butorphanol not only decreased the requirements of fentanyl but also enhanced hemodynamic stability in agitated patients suffering from ARF receiving NIV.
Trial Registration: Registered at http://www.chictr.org.cn/ (ChiCTR1800015534).
Keywords: butorphanol, acute respiratory failure, noninvasive ventilation
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]